CDGP affects over 100,000 boys in the US alone every year and qualifies as an Orphan Indication.
Key Issues with CDGP:
Delayed Sexual Development
Risk of Reduced Bone Mass
A typical short-course treatment (6-18) months will be investigated with our oral testestorone formulation in order to counter this condition. For those children (10%) with permanent hypogonadism, long-term supplementation is required. Without treatment, adolescent patients may suffer from failure to reach full height, educational impairment, adverse effects on skeletal proportions and bone mass and delayed sexual and psychosocial integration into society.
Many resources are available for adolescent boys & their parents to learn more about the diseases and available treatments. Currently no oral product is approved for testosterone replacement therapy.
Find-an-endocrinologist: www.hormone.org or call 1-800-HORMONE (1-800-467-6663)
Hormone health Network information: PCOS: www.hormone.org/Menopause/upload/polycystic- ovary-syndrome-bilingual-071509.pdf Klinefelter Syndrome: www.hormone.org/Resources/upload/FS_MH_Klinefelter_Syndrome_EN-6-12.pdf Turner Syndrome: www.hormone.org/Resources/upload/ FS_GD_Turner_Syndrome_EN-6-12.pdf MedlinePlus (National Institutes of health) information about puberty: www.nlm.nih.gov/medlineplus/puberty.html
Teenshealth (Nemours Foundation) information: "Delayed Puberty": kidshealth.org/teen/sexual_health/ changing_body/delayed_puberty.html "Everything You Wanted to Know about Puberty": kidshealth.org/teen/sexual_health/changing_body/ puberty.html?tracking=T_RelatedArticle